Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHARMACOKINETICS OF DEXTROMETHORPHAN AND DEXTRORPHAN IN EPILEPTIC PATIENTS
Autore:
KAZIS A; KIMISKIDIS V; NIOPAS I;
Indirizzi:
ARISTOTELIAN UNIV THESSALONIKI,SCH MED,G PAPANIKOLAOU HOSP,DEPT NEUROL C GR-57010 THESSALONIKI GREECE ARISTOTELIAN UNIV THESSALONIKI,SCH MED,DEPT NEUROL C GR-57010 THESSALONIKI GREECE ARISTOTELIAN UNIV THESSALONIKI,DEPT PHARM GR-57010 THESSALONIKI GREECE
Titolo Testata:
Acta neurologica Scandinavica
fascicolo: 2-3, volume: 93, anno: 1996,
pagine: 94 - 98
SICI:
0001-6314(1996)93:2-3<94:PODADI>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
METHYL-D-ASPARTATE; FOCAL CEREBRAL-ISCHEMIA; NMDA ANTAGONIST; 3 METABOLITES; HUMAN-LIVER; ANTITUSSIVES; POPULATION; MICROSOMES; INHIBITION; FLUOXETINE;
Keywords:
ANTICONVULSANTS; DEXTROMETHORPHAN; DEXTRORPHAN; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
A. Kazis et al., "PHARMACOKINETICS OF DEXTROMETHORPHAN AND DEXTRORPHAN IN EPILEPTIC PATIENTS", Acta neurologica Scandinavica, 93(2-3), 1996, pp. 94-98

Abstract

The present report describes the pharmacokinetic characteristics of dextromethorphan (DM) and its main active metabolite dextrorphan (DX) in a group of epileptic patients receiving comedication. Patients were sequentially dosed with DM 40 mg/6 h (8 weeks) and 50 mg/6 h (8 weeks)while concurrent antiepileptic drugs were kept stable. During baseline period, patients were phenotyped with regard to their drug metabolizing capacity. At the end of each treatment period, timed plasma DM andDX levels were determined post-dose by HPLC. Urine and cerebrospinal fluid (CSF) samples were also collected. The pharmacokinetic parameters of DM showed a wide intersubject variation. The genetic polymorphismof DM metabolism was identified as the possible cause of the observedvariability. For both DM and DX mean values for Cmax and AUC increased in a linear fashion with dose, while the mean values of tmax and t1/2 were not dependent on dose. The mean values of CL/F and Vss/F for DMwere also dose-dependent. 3-Methoxymorphinan, an N-demethylated metabolite of DM was detected in plasma and CSF of some patients and warrants further investigation as to its possible CNS effects. In conclusion, DM given in doses up to 50 mg/6 h can produce plasma and brain concentrations similar to the in vitro antiepileptic levels, without causing significant adverse effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 16:21:00